Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R, Kishida T, Sakaguchi M, Yokose T, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Yoshihara M, Nakamura Y, Miyagi Y, Sasada T. Jikuya R, et al. Among authors: sasada t. Cancer Immunol Immunother. 2020 Oct;69(10):2041-2051. doi: 10.1007/s00262-020-02608-6. Epub 2020 May 18. Cancer Immunol Immunother. 2020. PMID: 32424467 Free PMC article.
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Komatsu N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K. Noguchi M, et al. Among authors: sasada t. Cancer Immunol Immunother. 2015 Apr;64(4):493-505. doi: 10.1007/s00262-015-1660-1. Epub 2015 Feb 7. Cancer Immunol Immunother. 2015. PMID: 25662406 Free PMC article. Clinical Trial.
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K. Sakamoto S, et al. Among authors: sasada t. Cancer Sci. 2015 Oct;106(10):1257-63. doi: 10.1111/cas.12757. Epub 2015 Sep 25. Cancer Sci. 2015. PMID: 26212219 Free PMC article. Clinical Trial.
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
Araki H, Pang X, Komatsu N, Soejima M, Miyata N, Takaki M, Muta S, Sasada T, Noguchi M, Koda Y, Itoh K, Kuhara S, Tashiro K. Araki H, et al. Among authors: sasada t. Cancer Immunol Immunother. 2015 Dec;64(12):1565-73. doi: 10.1007/s00262-015-1756-7. Epub 2015 Oct 1. Cancer Immunol Immunother. 2015. PMID: 26428930 Free PMC article.
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K. Noguchi M, et al. Among authors: sasada t. Cancer Immunol Immunother. 2016 Feb;65(2):151-60. doi: 10.1007/s00262-015-1781-6. Epub 2016 Jan 4. Cancer Immunol Immunother. 2016. PMID: 26728480 Free PMC article. Clinical Trial.
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y. Takayama K, et al. Among authors: sasada t. J Immunol Res. 2016;2016:1745108. doi: 10.1155/2016/1745108. Epub 2016 May 4. J Immunol Res. 2016. PMID: 27274999 Free PMC article. Clinical Trial.
221 results